Albuminar® 25
Albumin (Human) U.S.P. 25
Albumin (Human) 25% is indicated in the emergency treatment of shock due to burns, trauma, operations, and infections; in the treatment of severe injuries; and in other similar conditions where the restoration of blood volume is urgent.
- Natural plasma protein product
- Safe and effective therapy for over 50 years
Broad Therapeutic Applications
- Plasma expansion and replacement - trauma, burns, and shock
- Conditions where restoration of blood volume is urgent
- Hypoproteinemia
Safety at the Source
- Source plasma screening for human immunodeficiency virus (HIV) 1 and 2 and for other vial indicators, including markers for hepatitis B virus and hepatitis C virus
- 100% of plasma comes from repeat donors, who are routinely tested at the time of each donation
Effective Viral Inactivation
- Pasteurization (heat treatment in aqueous solution) at 60°C for 10 hours - a demonstrated viral inactivation method that inactivates lipid-enveloped and certain non-lipid-enveloped viruses
NDC Number |
Product Description |
| 0053-7680-32 |
50 mL |
| 0053-7680-33 |
100 mL |
Important Safety Information
Albuminar® is contraindicated in patients with severe anemia or cardiac failure and in patients with a history of allergic reactions to human albumin.
Albuminar® is derived from human plasma, as with all plasma-derived products, the risk of transmission of infectious agents, including viruses, and theoretically, the Creutzfeldt-Jakob (CJD) disease agent, cannot be completely eliminated. As with any pharmaceutical, the physician should weigh the risks and benefits of administration.
Please see the
full prescribing information.
View universal billing codes for Albuminar®
CUSTOMER SUPPORT 1-800-683-1288 or
Customer Services
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit
www.fda.gov/medwatch or call 1-800-FDA-1088.
Last Updated: 22 May 2009